{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-119939","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.581911+00:00","generated_at":"2026-05-21T09:17:42.056520+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Inhibikase Q1 net loss $13.7M; advancing IKT-001 PAH Ph2b trial in H2 2025","bullets":["Net loss $13.7M ($0.15/share) vs $4.6M ($0.73) in Q1 2024; includes $7.4M non-cash acquisition charge for CorHepta.","R&D expenses $10.5M (incl. $7.4M IPR&D charge); SG&A $5.2M; cash $93.2M at March 31, 2025.","Appointed new CEO (Mark Iwicki), President/Head of R&D (Chris Cabell), CSO (John Adams), CFO (David McIntyre).","IKT-001 Phase 2b PAH study design finalizing; trial initiation expected H2 2025; FDA 'Study May Proceed' received Sept 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-119939","json":"https://secwatch.observer/filing/0001193125-25-119939.json","markdown":"https://secwatch.observer/filing/0001193125-25-119939.md","text":"https://secwatch.observer/filing/0001193125-25-119939.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525119939/0001193125-25-119939-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525119939/d940084d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:17:42.056520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}